Last reviewed · How we verify
NCT06736626: xDAPT
The xDAPT External Validation Study
trial testing Percutaneous coronary intervention in Coronary Artery Disease in 30,000 participants. Completed in 1 December 2024.
31 December 2022
Quick facts
| Lead sponsor | Icahn School of Medicine at Mount Sinai |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30,000 |
| Start date | 1 January 2012 |
| Primary completion | 31 December 2022 |
| Estimated completion | 1 December 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Percutaneous coronary intervention
Conditions studied
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
- Percutaneous Coronary Intervention — all drugs for Percutaneous Coronary Intervention →
Sponsor
Icahn School of Medicine at Mount Sinai
Who can join
18 and older, any sex, with Coronary Artery Disease or Percutaneous Coronary Intervention. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dual antiplatelet therapy (DAPT) is routinely recommended after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation to prevent thrombotic complications. However, DAPT is also associated with an increased risk of bleeding, which may have a similar or even greater impact on prognosis compared to recurrent ischemic events. To balance these risks, individualized risk stratification at the time of PCI is crucial for determining the optimal DAPT composition and duration, aiming to reduce thrombotic risk while minimizing bleeding complications. For this purpose, an artificial intelligence-based risk stratification tool (xDAPT, Abbott) was introduced and demonstrated strong clinical performance in its development study (ClinicalTrials.gov identifier: NCT06089304). This analysis aims to evaluate the performance of xDAPT in a real-world cohort of patients who underwent PCI over the past decade at a large urban center (Mount Sinai Hospital, New York).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06736626
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Percutaneous coronary intervention
Trials testing the same drug.
- NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
- NCT07457320 — Development and Validation of a Multimodal Artificial Intelligence Model for Early Prediction of Acute Myocardial Infarc · not yet recruiting
- NCT07449052 — Comprehensive Invasive Physiological Evaluation of Obstructive Coronary Artery Disease · NA · not yet recruiting
- NCT07250152 — Enhanced Prediction Model for Major Adverse Events Following Acute Myocardial Infarction · not yet recruiting
- NCT06399705 — REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities · Phase 3 · recruiting
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Icahn School of Medicine at Mount Sinai trials
Trials by the same sponsor.
- NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
- NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
- NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
- NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
- NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06736626 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
- Last refreshed: 24 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06736626.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing